注射用重组人尿激酶原联合利伐沙班对急性中危肺栓塞患者凝血功能、血气指标及NT-proBNP水平的影响  

Effects of Recombinant Human Prourokinase for Injection Combined with Rivaroxaban on Coagulation Function,Blood Gas Indexes and NT-proBNP Levels in Patients with Acute Intermediate-Risk Pulmonary Embolism

作　　者：王坤 何斐 杜茂宗 张学军[1] WANG Kun;HE Fei;DU Maozong;ZHANG Xuejun(Department of Cardiology,Henan Provincial Chest Hospital,Zhengzhou Henan 450000,China)

机构地区：[1]河南省胸科医院心内科,河南郑州450000

出　　处：《临床研究》2022年第3期14-17,共4页Clinical Research

基　　金：2021年联合共建项目(LHGJ20210234)。

摘　　要：目的探讨急性中危肺栓塞(PE)患者给予注射用重组人尿激酶原联合利伐沙班治疗对凝血功能、血气指标及N-末端脑钠肽前体(NT-proBNP)水平的影响。方法选取2019年12月至2021年12月在河南省胸科医院治疗的急性中危PE患者94例作为研究对象,按照随机数字表法分成观察组(47例)和对照组(47例),对照组给予利伐沙班治疗,观察组给予注射用重组人尿激酶原联合利伐沙班治疗,比较两组凝血功能、血气指标、NT-proBNP水平及不良反应。结果两组治疗后活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)明显延长,差异有统计学意义(P<0.05),纤维蛋白原(FIB)水平明显提高,差异有统计学意义(P<0.05),凝血调节蛋白(TM)、血浆D-二聚体(D-D)、血浆蛋白C(PC)水平明显降低,差异有统计学意义(P<0.05),与对照组相比,观察组APTT、PT明显更长,差异有统计学意义(P<0.05),FIB水平明显更高,差异有统计学意义(P<0.05),TM、D-D、PC水平明显更低,差异有统计学意义(P<0.05);两组治疗后血氧饱和度(SpO_(2))、动脉血氧分压(PaO_(2))水平明显提高,差异有统计学意义(P<0.05),二氧化碳分压(PaCO_(2))水平明显降低,差异有统计学意义(P<0.05),观察组SpO_(2)、PaO_(2)水平较对照组明显更高,差异有统计学意义(P<0.05),PaCO_(2)水平明显更低,差异有统计学意义(P<0.05);两组治疗后NT-proBNP水平明显降低,差异有统计学意义(P<0.05),观察组较对照组明显更低(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论急性中危PE患者给予注射用重组人尿激酶原联合利伐沙班治疗,能够改善凝血功能、血气指标及NT-proBNP水平,且不良反应较少。Objective To investigate the effect of recombinant human prourokinase for injection combined with rivaroxaban on coagulation function,blood gas indexes and the level of N-terminal pro-brain natriuretic peptide(NT-proBNP)in patients with acute intermediate-risk pulmonary embolism(PE).Methods A total of 94 patients with acute intermediate-risk PE who were treated in Henan Provincial Chest Hospital from December 2019 to December 2021 were selected as the research objects,and they were divided into the observation group(47 cases)and the control group(47 cases)according to the random number table method.The control group was given rivaroxaban treatment,the observation group was given recombinant human prourokinase for injection combined with rivaroxaban treatment.The coagulation function,blood gas indexes,NT-proBNP levels and adverse reactions were compared between the two groups.Results After treatment,activated partial thromboplastin time(APTT)and prothrombin time(PT)in the two groups were significantly prolonged(P<0.05),fibrinogen(FIB)levels were significantly increased(P<0.05),thrombomodulin(TM),plasma D-dimer(DD),and plasma protein C(PC)levels were significantly decreased(P<0.05),compared with the control group,APTT and PT in the observation group were significantly longer(P<0.05),and the level of FIB was significantly higher(P<0.05),TM,DD,PC levels were significantly lower(P<0.05).After treatment,blood oxygen saturation(SpO_(2))and arterial partial pressure of oxygen(PaO_(2))levels were significantly increased in the two groups(P<0.05),the partial pressure of carbon dioxide(PaCO_(2))was significantly decreased(P<0.05),the levels of SpO_(2) and PaO_(2) in the observation group were significantly higher than those in the control group(P<0.05),and the level of PaCO_(2) was significantly lower(P<0.05).The level of NT-proBNP in the two groups was significantly decreased(P<0.05),and the observation group was significantly lower than the control group(P<0.05).There was no significant difference in the incidence of adve

关 键 词：注射用重组人尿激酶原 利伐沙班 急性中危肺栓塞 凝血功能 

分 类 号：R563.5[医药卫生—呼吸系统]